Current Status of Messenger RNA Delivery Systems

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 158-165

  Stanton, Matthew G ^a  

^a Generation Bio   (United States)

Author keywords

delivery; mRNA; nanotechnology

Indexed keywords

ENZYME; MESSENGER RNA; PROTEIN; VACCINE; LIPID; NANOPARTICLE; SIGNAL PEPTIDE;

ARTICLE; ENZYME REPLACEMENT; GENE DELIVERY SYSTEM; HUMAN; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL (TOPIC); ENDOSOME; GENE THERAPY; GENE TRANSFER; GENETICS; METABOLISM; NEOPLASM; NUCLEAR REPROGRAMMING; PATHOLOGY; PROCEDURES; STEM CELL; WOUND HEALING;

ANIMALS; CARDIOVASCULAR DISEASES; CELLULAR REPROGRAMMING; CLINICAL TRIALS AS TOPIC; ENDOSOMES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPIDS; NANOPARTICLES; NEOPLASMS; RNA, MESSENGER; STEM CELLS; WOUND HEALING;

EID: 85048364463     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2018.0726     Document Type: Article

References (53)

1. Jaczmarek JC, PS Kowalski and DG Anderson. (2017). Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Medicine 9:60.
2. Stanton MG and KE Murphy-Benenato. (2017). Messenger RNA as a novel therapeutic approach. In: Topics in Medicinal Chemistry. Garner AL, ed. Basel, Switzerland: Springer International Publishing AG, pp 237-253.
3. Karikó K, H Muramatsu, J Ludwig and D Weissman. (2011). Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-coding mRNA. Nucleic Acids Res 39:e142.
4. Karikó K, M Buckstein, H Ni and D Weissman. (2005). Suppression of RNA recognition by tolllike receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23:165-175.
5. Karikó K, H Muramatsu, FA Welsh, J Ludwig, H Kato, S Akira and D Weissman. (2008). Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16:1833-1840.
6. Nallagatla SR and PC Bevilacqua. (2008). Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 14:1201-1213.
7. Anderson BR, H Muramatsu, SR Nallagatla, PC Bevilacqua, LH Sansing, D Weissman and K Karikó. (2010). Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res 38:5884-5892.
8. Warren L, PD Manos, T Ahfeldt, Y-H Loh, H Li, F Lau, W Ebina, PK Mandal, ZD Smith, et al. (2010). Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618-630.
9. Khalid AH and KA Whitehead. (2017). Tools for translation: non-viral materials for therapeutic mRNA delivery. Nat Rev Mater 2:17056.
10. Varkouhi AK, M Scholte, G Storm and HJ Haisma. (2016). Endosomal escape pathways for delivery of biologicals. J Control Release 151:220-228.
11. Zolnik BS, Á González-Fernández, N Sadrieh and MA Dobrovolskaia. (2010). Nanoparticles and the immune system. Endocrinology 151:458-465.
12. Kreiter S, A Selmi, M Diken, M Koslowski, CM Britten, C Huber, O Türeci and U Sahin. (2010). Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 70: 9031-9040.
13. Scheel B, S Braedel, J Probst, JP Carralot, H Wagner, H Schild, G Jung, HG Rammensee and S Pascolo. (2004). Immunostimulating capacities of stabilized RNA molecules. Eur J Immunol 34:537-547.
14. Scheel B, R Teufel, J Probst, JP Carralot, J Geginat, M Radsak, D Jarrossay, H Wagner, G Jung, et al. (2005). Tolllike receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 35:1557-1566.
15. Alberer M, U Gnad-Vogt, HS Hong, KT Mehr, L Backert, G Finak, R Gottardo, MA Bica, A Garofano, et al. (2017). Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390:1511-1520.
16. Kübler H, B Scheel, U Gnad-Vogt, K Miller, W Schultze- Seemann, F Vom Dorp, G Parmiani, C Hampel, S Wedel, et al. (2015). A self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. J Immunother Cancer 3:26.
17. Kranz LM, M Diken, H Haas, S Kreiter, C Loquai, KC Reuter, M Meng, D Fritz, F Vascotto, et al. (2016). Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534:396-401.
18. Grabbe S, H Haas, M Diken, LM Kranz, P Langguth and U Sahin. (2016). Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma. Nanomedicine 11:2723-2734.
19. Sahin U, E Derhovanessian, M Miller, BP Kloke, P Simon, M Löwer, V Bukur, AD Tadmor, U Luxemburger, et al. (2017). Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222-226.
20. Cullis PR and MJ Hope. (2017). Lipid nanoparticle systems for enabling gene therapies. Mol Ther 25:1467-1475.
21. Richner JM, S Himansu, KA Dowd, SL Butler, V Salazar, JM Fox, JG Julander, WW Tang, S Shresta, et al. (2017). Modified mRNA vaccines protect against zika virus infection. Cell 168:1114-1125.
22. Pardi N, MJ Hogan, RS Pelc, H Muramatsu, H Andersen, CR DeMaso, KA Dowd, LL Sutherland, RM Scearce, et al. (2017). Zika virus protection by a single low-dose nucleosidemodified mRNA vaccination. Nature 543:248-251.
23. Lutz J, S Lazzoro, M Habbeddine, KE Schmidt, P Baumhof, BL Mui, YK Tam, TD Madden, MJ Hope, et al. (2017). Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2:29.
24. Geall AJ, A Verma, GR Otten, CA Shaw, A Hekele, K Banerjee, Y Cu, CW Beard, LA Brito, et al. (2012). Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A 109:14604-14609.
25. Bahl K, JJ Senn, O Yuzhakov, A Bulychev, LA Brito, KJ Hassett, ME Laska, M Smith, Ö Almarsson, et al. (2017). Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10 N8 and H7 N9 influenza viruses. Mol Ther 25:1316-1327.
26. Hekele A, S Bertholet, J Archer, DG Gibson, G Palladino, LA Brito, GR Otten, M Brazzoli, S Buccato, et al. (2013). Rapidly produced SAM® vaccine against H7 N9 influenza is immunogenic in mice. Emerg Microb Infect 2:e52.
27. Broos K, K Van der Jeught, J Puttemans, C Goyvaerts, C Heirman, H Dewitte, R Verbeke, I Lentacker, K Thielemans and K Breckpot. (2016). Particle-mediated intravenous delivery of antigen mRNA results in strong antigenspecific T-cell responses despite the induction of type I interferon. Mol Ther Nucleic Acids 5:e326.
28. Oberli MA, AM Reichmuth, JR Dorkin, MJ Mitchell, OS Fenton, A Jaklenec, DG Anderson, R Langer and D Blankschtein. (2017). Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett 17: 1326-1335.
29. Zangi L, KO Lui, A von Gise, Q Ma, W Ebina, LM Ptaszek, D Später, H Xu, M Tabebordbar, et al. (2013). Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 31:898-907.
30. Van der Jeught K, PT Joe, L Bialkowski, C Heirman, L Daszkiewicz, T Liechtenstein, D Escors, K Thielemans and K Breckpot. (2014). Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget 5:10100-10113.
31. Van Lint S, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, C Goyvaerts, S Du Four, K Van der Jeught, et al. (2016). Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells. Cancer Immunol Res 4:146-156.
32. Uchida S, H Kinoh, T Ishii, A Matsui, TA Tockary, KM Takeda, H Uchida, K Osada, K Itaka and K Kataoka. (2016). Systemic delivery of messenger RNA for the treatment of pancreatic cancer using polyplex nanomicelles with a cholesterol moiety. Biomaterials 82:221-228.
33. Pardi N, S Tuyishime, H Muramatsu, K Kariko, BL Mui, YK Tam, TD Madden, MJ Hope and D Weissman. (2015). Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 217:345-351.
34. Jayaraman M, SM Ansell, BL Mui, YK Tam, J Chen, X Du, D Butler, L Eltepu, S Matsu, et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl 51:8529-8533.
35. Maier MA, M Jayaraman, S Matsuda, J Liu, S Barros, W Querbes, YK Tam, SM Ansell, V Kumar, et al. (2013). Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther 21:1570-1578.
36. Akinc A, W Querbes, S De, J Qin, M Frank-Kamenetsky, KN Jayaprakash, M Jayaraman, KG Rajeev, WL Cantley, et al. (2010). Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 18:1357-1364.
37. Nabhan JF, KM Wood, VP Rao, J Morin, S Bhamidipaty, TP LaBranche, RL Gooch, F Bozal, CE Bulawa and BC Guild. (2016). Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia. Sci Rep 6:20019.
38. Kaczmarek JC, AK Patel, KJ Kauffman, OS Fenton, MJ Webber, MW Heartlein, F DeRosa and DG Anderson. (2016). Polymer-lipid nanoparticles for systemic delivery of mRNA to the lungs. Angew Chem Int Ed Engl 55: 13808-13812.
39. Thess A, S Grund, BL Mui, MJ Hope, P Baumhof, M Fotin- Mleczek and T Schlake. (2015). Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23: 1456-1464.
40. Ramaswamy S, N Tonnu, K Tachikawa, P Limphong, JB Vega, PP Karmali, P Chivukula and IM Verma. (2017). Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A 114: E1941-E1950.
41. Love KT, KP Mahon, CG Levins, KA Whitehead, W Querbes, JR Dorkin, J Qin, W Cantley, LL Qin, et al. (2010). Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A 107:1864-1869.
42. Kauffman KJ, JR Dorkin, JH Yang, MW Heartlein, F De- Rosa, FF Mir, OS Fenton and DG Anderson. (2015). Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett 15:7300-7306.
43. DeRosa F, B Guild, S Karve, L Smith, K Love, JR Dorkin, KJ Kauffman, J Zhang, B Yahalom, DG Anderson and MW Heartlein. (2016). Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system. Gene Ther 23:699-707.
44. Fenton OS, KJ Kauffman, RL McClellan, EA Appel, JR Dorkin, MW Tibbitt, MW Heartlein, F DeRosa, R Langer and DG Anderson. (2016). Bioinspired alkenyl amino alcohol ionizable lipid materials for highly potent in vivo mRNA delivery. Adv Mater 28:2939-2943.
45. Li B, X Luo, B Deng, J Wang, DW McComb, Y Shi, KM Gaensler, X Tan, AL Dunn, BA Kerlin and Y Dong. (2015). An orthogonal array optimization of lipid-like nanoparticles for mRNA delivery in vivo. Nano Lett 15:8099-8107.
46. Li B, X Luo, B Deng, JB Giancola, DW McComb, TD Schmittgen and Y Dong. (2016). Effects of local structural transformation of lipid-like compounds on delivery of messenger RNA. Sci Rep 6:22137.
47. Jarzȩbińska A, T Pasewald, J Lambrecht, O Mykhaylyk, L Kümmerling, P Beck, G Hasenpusch, C Rudolph, C Plank and C Dohmen. (2016). A single methylene group in oligoalkylamine-based cationic polymers and lipids promotes enhanced mRNA delivery. Angew Chem Int Ed Engl 55:9591-9595.
48. Dong Y, JR Dorkin, W Wang, PH Chang, MJ Webber, BC Tang, J Yang, I Abutbul-Ionita, D Danino, et al. (2016). Poly(glycoamidoamine) brushes formulated nanomaterials for systemic siRNA and mRNA delivery in vivo. Nano Lett 16:842-848.
49. McKinlay CL, JR Vargas, TR Blake, JW Hardy, M Kanada, CH Contag, PA Wender and RM Waymouth. (2017). Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals. Proc Natl Acad Sci U S A 114:E448-E456.
50. Chen Q, R Qi, X Chen, X Yang, S Wu, H Xiao and W Dong. (2017). A targeted and stable polymeric nanoformulation enhances systemic delivery of mRNA to tumors. Mol Ther 25:92-101.
51. An D, JL Schneller, A Frassetto, S Liang, X Zhu, J-S Park, M Theisen, S-J Hong, J Zhou, et al. (2017). Systemic messenger RNA therapy as a treatment for methylmalonic acidemia. Cell Rep 21:3548-3558.
52. Servik K. (2017). Can a multibillion-dollar biotech prove its RNA drugs are safe for a rare disease? Science.
53. Patel S, N Ashwanikumar, E Robinson, A DuRoss, C Sun, KE Murphy-Benenato, C Mihai, Ö Almarsson and G Sahay. (2017). Boosting intracellular delivery of lipid nanoparticleencapsulated mRNA. Nano Lett 17:5711-5718.